MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Chronic Liver DiseaseCirrhosisEsophageal VaricesPortal HypertensionBleeding
Interventions
DEVICE

Methacetin (with Breath testing device)

The methacetin is enriched with carbon 13, a stable non- radioactive isotope, and has been found to be safe in hundreds of studies. The material is very similar to acetominophen. 75 milligrams (mm) of this material pre- dissolved in water are used. This material undergoes rapid metabolism by the liver.

Trial Locations (1)

34362

Carmel Medical Center, Haifa

Sponsors
All Listed Sponsors
lead

Meridian Bioscience, Inc.

INDUSTRY

NCT01851252 - MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy | Biotech Hunter | Biotech Hunter